Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corp. operated as a commercial-stage biopharmaceutical company developing and commercializing vaccines, with recurring announcements centered on its marketed products, pipeline and corporate status. The company commercialized HEPLISAV-B® vaccine, a hepatitis B vaccine approved in the U.S., European Union and United Kingdom for adults, and CpG 1018® adjuvant, which is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines.
Recurring updates include HEPLISAV-B revenue and financial results, share repurchase authorizations, investor conference presentations, licensing and collaboration activity, and clinical disclosures for vaccine candidates such as Z-1018 for shingles. Coverage also includes governance changes, material agreements, shareholder voting matters, capital-structure disclosures and public-company status updates.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on June 9 at 12:00 p.m. C.T. The presentation will be accessible via the Company’s website under the 'Events & Presentations' section. Dynavax is known for developing novel vaccines, including HEPLISAV-B, approved in 2018 for hepatitis B prevention in adults. The company is also advancing CpG 1018 as a vaccine adjuvant through partnerships.
Dynavax Technologies Corporation (Nasdaq: DVAX) has successfully closed its underwritten public offering of 16,100,000 shares at $5.00 per share, generating approximately $80.5 million in gross proceeds. The offering included the underwriters' option to purchase an additional 2,100,000 shares. Proceeds will be utilized to support the commercialization of HEPLISAV-B®, advance its CpG 1018 vaccine platform, and enhance general corporate purposes. The offering was managed by Cowen, Evercore ISI, and William Blair, with a shelf registration statement filed with the SEC.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced a public offering of 14,000,000 shares at $5.00 each, aiming to raise approximately $70 million. This offering, set to close around May 27, 2020, includes a 30-day option for underwriters to purchase an additional 2,100,000 shares. The funds will support the commercialization of HEPLISAV-B® and advancements in the CpG 1018 vaccine platform, potentially for COVID-19. The offering is conducted under a previously effective shelf registration statement filed with the SEC.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced plans for an underwritten public offering to sell shares of its common stock, with a potential 15% over-allotment option for underwriters. Proceeds are intended to support the commercialization of HEPLISAV-B®, advance the CpG 1018 vaccine platform, and cover general corporate expenses. The offering follows a shelf registration statement effective since April 30, 2020. The company emphasizes that the timing and size of the offering depend on market conditions.
Dynavax Technologies Corporation (DVAX) reported Q1 2020 net product revenue of $10.5 million, up from $5.6 million in Q1 2019, driven by increased sales of HEPLISAV-B, despite COVID-19 challenges. The company achieved a seroprotection rate of 86.4% in preliminary results from a clinical trial for dialysis patients. While total R&D expenses decreased, SG&A expenses rose to $20.9 million. A net loss of $12.6 million was reported, an improvement from $39.7 million in the previous year. Dynavax maintains a strong cash position with $129.5 million as of March 31, 2020.
Summary not available.